New York, New York (PRWEB) January 30, 2014 -- The multidistrict litigation established in Illinois federal court for Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continues to move forward, Bernstein Liebhard LLP reports. According to court documents, a status conference was convened in the U.S. District Court, Southern District of Illinois on January 24, 2014, at which time various discovery issues were addressed. The Court also scheduled the proceeding’s next status conference for March 5, 2014 at 10:30 a.m. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“Our Firm has received numerous inquiries from Pradaxa patients who allegedly suffered gastrointestinal hemorrhage, cerebral hemorrhage, and other episodes of life-threatening internal bleeding due to this medication. We are pleased to see that federal Pradaxa lawsuits are moving forward,” says Bernstein Liebhard LLP, nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who may have been harmed by this blood thinner.
Pradaxa Bleeding Allegations
According to court documents, more than 2,131 Pradaxa bleeding claims are currently pending in the federal multidistrict litigation. The claims accuse Boehringer Ingelheim of failing to adequately warn doctors and patients about the drug’s potential to cause serious internal bleeding. Specifically, plaintiffs allege that the company failed to warn that there was no readily available antidote to reverse Pradaxa bleeding.
Court records indicate that the first federal trial of a Pradaxa lawsuit will get underway in August 2014 in the Southern District of Illinois. Earlier this month, cases were selected for the proceeding’s first four trials. Two of those will involve wrongful death claims, while the remaining two trials will involve lawsuits that allege Pradaxa caused serious gastrointestinal bleeds.
The U.S. Food & Drug Administration (FDA) announced in December that it would begin a new, large-scale assessment of Pradaxa bleeding rates in relation to warfarin, a blood thinner that has been on the market for decades. Unlike Pradaxa, internal bleeding that sometimes occurs with warfarin can be stopped via the administration of vitamin K.
The announcement of the FDA assessment follows the publication of a study in April by the Institute of Safe Medicine Practices that found Pradaxa had been named in more than 3,200 FDA adverse event reports in 2012, the most of any drug monitored by the agency. Of those, more than 580 involved a patient death. By contrast, warfarin was named in only 861 incident reports, including 56 deaths.*
Alleged victims of Pradaxa bleeding may be entitled to compensation for their injury-related damages. To learn more about filing a Pradaxa lawsuit please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to schedule a free, no obligation case review.
*ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Felecia L. Stern, Pradaxa Lawsuit Information Center, http://www.pradaxalawsuithelp.com/, +1 800-511-5092, [email protected]